“Cost Effectiveness of Pembrolizumab Vs Chemotherapy As First-Line Treatment for Metastatic NSCLC That Expresses High Levels of PD-L1 in Switzerland”. Swiss Medical Weekly 149, no. 5152 (December 27, 2019): w20170. Accessed October 14, 2025. https://www.smw.ch/index.php/smw/article/view/2711.